Published in J Leukoc Biol on April 22, 2008
How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol (2010) 2.11
Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis (2016) 1.55
Human dendritic cell subsets. Immunology (2013) 1.49
Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis (2010) 1.29
Tolerogenic dendritic cells and their role in transplantation. Semin Immunol (2011) 1.26
LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol (2008) 1.23
Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant (2013) 1.22
Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol (2013) 1.09
Tolerogenic dendritic cells: all present and correct? Am J Transplant (2010) 0.97
Human tolerogenic DC-10: perspectives for clinical applications. Transplant Res (2012) 0.93
Tolerogenic dendritic cell-regulatory T-cell interaction and the promotion of transplant tolerance. Transplantation (2009) 0.92
Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol (2009) 0.90
Cell therapy using tolerogenic dendritic cells in transplantation. Transplant Res (2012) 0.89
Protection of islet grafts through transforming growth factor-β-induced tolerogenic dendritic cells. Diabetes (2013) 0.89
Bronchial epithelial cells cultured from clinically stable lung allograft patients promote the development of macrophages from monocytes rather than dendritic cells. Thorax (2009) 0.88
Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells. PLoS One (2011) 0.88
Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model. PLoS One (2010) 0.87
Regulatory dendritic cell therapy: from rodents to clinical application. Immunol Lett (2013) 0.87
Rhesus monkey immature monocyte-derived dendritic cells generate alloantigen-specific regulatory T cells from circulating CD4+CD127-/lo T cells. Transplantation (2009) 0.85
Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation. J Transplant (2013) 0.85
IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals. J Clin Immunol (2010) 0.83
Regulatory myeloid cells in transplantation. Transplantation (2014) 0.83
Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for regulation and therapy of liver auto- and alloimmunity. Immunobiology (2010) 0.82
Evaluation of the Effect of the 47 kDa Protein Isolated from Aged Garlic Extract on Dendritic Cells. Iran J Basic Med Sci (2012) 0.81
Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron (2013) 0.81
Gram-negative enterobacteria induce tolerogenic maturation in dexamethasone conditioned dendritic cells. PLoS One (2012) 0.80
Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications. Immune Netw (2016) 0.80
Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2. J Immunol (2014) 0.79
Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther (2013) 0.79
Gene Expression Profiling of Human Monocyte-derived Dendritic Cells - Searching for Molecular Regulators of Tolerogenicity. Front Immunol (2015) 0.78
Tolerogenic dendritic cells produced by lentiviral-mediated CD40- and interleukin-23p19-specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing T helper type 17 cells. Clin Exp Immunol (2014) 0.78
Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation. Front Immunol (2016) 0.77
Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4(+) T cells partly via transforming growth factor-β1. Clin Exp Immunol (2016) 0.77
Eomesoderminlo CTLA4hi Alloreactive CD8+ Memory T Cells Are Associated With Prolonged Renal Transplant Survival Induced by Regulatory Dendritic Cell Infusion in CTLA4 Immunoglobulin-Treated Nonhuman Primates. Transplantation (2016) 0.77
Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4(+) T Cells. Front Immunol (2016) 0.76
Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity. Front Immunol (2015) 0.76
Dexamethasone preconditioning improves the response of collagen-induced arthritis to treatment with short-term lipopolysaccharide-stimulated collagen-loaded dendritic cells. Clin Dev Immunol (2013) 0.76
Nematodes and human therapeutic trials for inflammatory disease. Parasite Immunol (2016) 0.75
Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders. Exp Ther Med (2016) 0.75
Treatment with Dexamethasone and Monophosphoryl Lipid A Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers Tolerogenic Features. Front Immunol (2016) 0.75
Downregulation of the Syk Signaling Pathway in Intestinal Dendritic Cells Is Sufficient To Induce Dendritic Cells That Inhibit Colitis. J Immunol (2016) 0.75
Rel B-modified dendritic cells possess tolerogenic phenotype and functions on lupus splenic lymphocytes in vitro. Immunology (2016) 0.75
Continuous retinoic acid induces the differentiation of mature regulatory monocytes but fails to induce regulatory dendritic cells. BMC Immunol (2014) 0.75
miRNA signatures can predict acute liver failure in hepatitis E infected pregnant females. Heliyon (2017) 0.75
Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype. Immunology (2017) 0.75
Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother (2014) 0.75
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol (2007) 6.92
Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med (2000) 6.45
Induction of tolerance by IL-10-treated dendritic cells. J Immunol (1997) 4.65
Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity (2003) 3.28
IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol (2001) 3.13
B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med (1994) 2.85
Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol (1999) 2.79
Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood (2004) 2.76
High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med (1994) 2.70
Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med (1994) 2.70
Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol (2006) 2.56
Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med (2002) 2.37
Differentiation of T regulatory cells by immature dendritic cells. J Exp Med (2001) 2.35
Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol (2000) 2.24
Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol (2000) 2.17
Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity (2003) 1.97
Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest (2001) 1.66
In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy. J Immunol (2004) 1.45
The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol (2000) 1.45
Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood (2003) 1.41
Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity (2003) 1.41
"Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol (2006) 1.30
The challenge of inhibiting alloreactive T-cell memory. Am J Transplant (2006) 1.28
Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol (2001) 1.27
Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells. Am J Transplant (2006) 1.24
Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol (2004) 1.17
Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J Immunol (2007) 1.12
Retracted Role of interleukin 12 and costimulators in T cell anergy in vivo. J Exp Med (1997) 1.12
Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther (2000) 1.10
Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol (2002) 1.07
Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donor-specific allograft hyporesponsiveness. Transplantation (2006) 1.07
G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation. J Immunol (2002) 1.06
Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. J Immunol (1998) 1.06
On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J Immunol (1998) 1.05
Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis Rheum (2004) 1.04
Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells. Transplantation (2003) 1.03
Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood (2006) 1.00
Cellular requirements for renal allograft rejection in the athymic nude rat. J Exp Med (1989) 0.97
Persistence of peptide-induced CD4+ T cell anergy in vitro. J Exp Med (1998) 0.96
Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations. Am J Transplant (2006) 0.95
Th2 cytokine profile in infants predisposes to improved graft acceptance after liver transplantation. Transplantation (2001) 0.95
Aspirin-treated human DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Am J Transplant (2006) 0.94
Differences between responses of naive and activated T cells to anergy induction. J Immunol (1998) 0.92
Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol (2003) 0.90
Differential infiltration by CD45RO and CD45RA subsets of T cells associated with human heart allograft rejection. Am J Pathol (1993) 0.89
Naive T cells are resistant to anergy induction by anti-CD3 antibodies. J Immunol (2004) 0.87
Generation of antigen-specific, interleukin-10-producing T-cells using dendritic cell stimulation and steroid hormone conditioning. Transpl Immunol (2003) 0.86
Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl (2007) 0.85
Implication of Th1, Th2, and Th3 cytokines in liver graft acceptance. Transplant Proc (1999) 0.84
Costimulatory effect of IL-12 on the activation of naive, memory CD4+ T cells, and Th1 clone. Cell Immunol (1997) 0.81
A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol (1997) 0.81
Tolerance induction of human CD4+ T cells: markedly enhanced sensitivity of memory versus naive T cells to peripheral anergy. Cell Immunol (1993) 0.78
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity (2012) 3.58
Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood (2011) 3.16
The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J Exp Med (2011) 2.96
IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity (2013) 2.69
Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol (2007) 2.19
Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. Arthritis Care Res (Hoboken) (2014) 2.11
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2010) 2.08
Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol (2003) 2.05
The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis (2012) 2.03
Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J Exp Med (2009) 1.96
Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum (2010) 1.86
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med (2013) 1.67
Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis (2009) 1.62
Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood (2002) 1.57
Integrated safety in tocilizumab clinical trials. Arthritis Res Ther (2011) 1.55
In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov (2007) 1.45
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum (2011) 1.44
Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis (2013) 1.37
Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis (2010) 1.29
Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol (2011) 1.27
Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest (2014) 1.25
Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol (2010) 1.24
LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol (2008) 1.23
Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays. J Biol Chem (2002) 1.20
Anti-TNF therapy. Best Pract Res Clin Rheumatol (2011) 1.18
Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum (2012) 1.17
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet (2008) 1.16
Low-strength T-cell activation promotes Th17 responses. Blood (2010) 1.15
Sustained IL-12 signaling is required for Th1 development. J Immunol (2004) 1.15
Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther (2006) 1.13
A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J Immunol (2005) 1.12
FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. PLoS One (2012) 1.07
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis (2010) 1.06
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res Ther (2004) 1.04
Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci (2004) 1.03
A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. Ann Rheum Dis (2012) 1.02
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum (2008) 1.01
Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther (2012) 1.00
Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice. Arthritis Res Ther (2006) 0.99
Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. Ann Rheum Dis (2010) 0.99
Regulatory T cells and autoimmunity. Curr Opin Hematol (2009) 0.98
Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2009) 0.97
Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis (2010) 0.96
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol (2004) 0.95
The c-Rel subunit of NF-κB regulates epidermal homeostasis and promotes skin fibrosis in mice. Am J Pathol (2013) 0.94
Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. Hum Mutat (2012) 0.94
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis (2010) 0.93
Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. Arthritis Res Ther (2006) 0.91
Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. Hum Mol Genet (2002) 0.91
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics (2009) 0.91
High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis Rheum (2002) 0.90
The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. Arthritis Rheum (2006) 0.90
Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther (2013) 0.90
Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann Rheum Dis (2011) 0.90
Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required? Arthritis Res Ther (2013) 0.90
Profound invariant natural killer T-cell deficiency in inflammatory arthritis. Ann Rheum Dis (2010) 0.88
Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol (2008) 0.87
Treg cells in rheumatoid arthritis: an update. Curr Rheumatol Rep (2013) 0.87
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Ann Rheum Dis (2009) 0.87
Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Res Ther (2012) 0.86
CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Allergy Clin Immunol (2005) 0.86
Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort. Ann Rheum Dis (2011) 0.85
Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology (Oxford) (2011) 0.85
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther (2014) 0.85
Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming. Transplantation (2009) 0.84
Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat Rev Rheumatol (2011) 0.84
In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of Graft-versus-host disease. Transplantation (2005) 0.83
Regulatory T cells inhibit CD8(+) T-cell tissue invasion in human skin graft-versus-host reactions. Transplantation (2012) 0.83
Immune reconstitution and graft-versus-host reactions in rat models of allogeneic hematopoietic cell transplantation. Front Immunol (2012) 0.83
Suppression of cellular immunity by cord blood-derived unrestricted somatic stem cells is cytokine-dependent. J Cell Mol Med (2008) 0.82
Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells. Transplantation (2008) 0.82
What can rheumatologists learn from translational cancer therapy? Arthritis Res Ther (2013) 0.82
Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenet Genomics (2010) 0.81
Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. Rheumatology (Oxford) (2012) 0.81
T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice. Ann Rheum Dis (2006) 0.81
Tregs and rheumatoid arthritis. Acta Reumatol Port (2008) 0.81
A novel paradigm for dendritic cells as effectors of cartilage destruction. Rheumatology (Oxford) (2009) 0.80
Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands. Leuk Lymphoma (2012) 0.80
Disease activity and cognition in rheumatoid arthritis: an open label pilot study. Arthritis Res Ther (2012) 0.79
Treating to re-establish tolerance in inflammatory arthritis - lessons from other diseases. Best Pract Res Clin Rheumatol (2010) 0.79